TY - JOUR
T1 - Roles of aldosterone in vascular calcification
T2 - An update
AU - Gao, Jingwei
AU - Zhang, Kun
AU - Chen, Jie
AU - Wang, Mong-Heng
AU - Wang, Jingfeng
AU - Liu, Pinming
AU - Huang, Hui
N1 - Funding Information:
This work was supported in part by NSFC [ 81422011, 81370837 and 81500563 ], and the Natural Science Foundation of Guangdong Province [ 2014A030313035 ] to Hui Huang. In addition, an American Heart Association Grant-in-Aid Grant ( AHASE 00090 ) to M. H. Wang.
Publisher Copyright:
© 2016 Elsevier B.V. All rights reserved.
PY - 2016
Y1 - 2016
N2 - Both clinical and experimental studies have demonstrated that vascular calcification (VC) is a common pathology shared in many chronic diseases such as chronic kidney disease (CKD) and diabetes. It's an independent risk factor for cardiovascular events. Since the pathogenesis of VC is complicated, current therapies have limited effects on the regression of VC. Therefore, it is urgent to investigate the potential mechanisms and find new targets for the treatment of VC. Aldosterone (Aldo), a mineralocorticoid hormone, is the metabolite of renin-angiotensin-aldosterone system (RAAS) activation, which can exert genomic and non-genomic effects on the cardiovascular system. Recent data suggests that Aldo can promote VC. Here, we summarized the roles of Aldo in the process of VC and a series of findings indicated that Aldo could act as a potentially therapeutic target for treating VC.
AB - Both clinical and experimental studies have demonstrated that vascular calcification (VC) is a common pathology shared in many chronic diseases such as chronic kidney disease (CKD) and diabetes. It's an independent risk factor for cardiovascular events. Since the pathogenesis of VC is complicated, current therapies have limited effects on the regression of VC. Therefore, it is urgent to investigate the potential mechanisms and find new targets for the treatment of VC. Aldosterone (Aldo), a mineralocorticoid hormone, is the metabolite of renin-angiotensin-aldosterone system (RAAS) activation, which can exert genomic and non-genomic effects on the cardiovascular system. Recent data suggests that Aldo can promote VC. Here, we summarized the roles of Aldo in the process of VC and a series of findings indicated that Aldo could act as a potentially therapeutic target for treating VC.
KW - Aldosterone
KW - Genomic mechanisms
KW - Non-genomic mechanisms
KW - Vascular calcification
KW - Vascular smooth muscle cells
UR - http://www.scopus.com/inward/record.url?scp=84974539590&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84974539590&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2016.05.030
DO - 10.1016/j.ejphar.2016.05.030
M3 - Review article
C2 - 27238972
AN - SCOPUS:84974539590
SN - 0014-2999
VL - 786
SP - 186
EP - 193
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
ER -
